How do I know that the Genesis Serenity prenatal test is effective?

How do I know the Genesis Serenity prenatal test is effective?

Recently the first NIPT randomised control clinical trial was reported in the prestigious New England Journal of Medicine titled “DNA sequencing versus standard prenatal aneuploidy screening” by Bianchi et al (NEJM, Feb 27th 2014, volume 370, number 9). The paper showed how the verifi® prenatal test was used to look at 1914 women of all risk groups, for trisomies 21 and 18, reporting that “the false positive rates with cfDNA (verifi®) testing were significantly lower than those with standard screening (0.3% vs. 3.6% for trisomy 21, P<0.001; and 0.2% vs. 0.6% for trisomy 18, P = 0.03)”.

In this group of patients verifi® also successfully detected trisomy 13, 18 and 21 in all cases with confirmed trisomies. Finally “positive predictive values for cfDNA (verifi®) testing versus standard screening were 45.5% versus 4.2% for trisomy 21 and 40.0% versus 8.3% for trisomy 18″.

The New England Journal of Medicine editorial concluded “the significantly and substantively lower false positive rates with cfDNA (verifi®) screening than with standard screening, augurs well for pregnant women and their foetuses”.

About Us

Genesis Genetics is the pioneer of preimplantation testing of embryos for inherited genetic abnormalities, and was founded by world renowned scientists largely responsible for discovering preimplantation genetic diagnosis (PGD) as a clinical practice and performed the first successful cases in the world.

 

Contact Genesis Genetics

London Biosciences Innovation Centre
London NW1 0NH
Phone: +44 (0)20 7691 2084
Email: ggeulab1@genesisgenetics.org
Join Us on Facebook »
website security